Edesa Biotech RPE
Mi az Edesa Biotech RPE?
A RPE az Edesa Biotech, Inc. - $0.00
Mi a RPE meghatározása?
Egy alkalmazottra jutó bevétel (RPE) a bevétel osztva a szervezet alkalmazottai számával.
RPE a Health Care szektor a NASDAQ-on cégekben a Edesa Biotech -hoz képest
Mit csinál Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
rpe -hoz hasonló cégek Edesa Biotech
- Imperial Pacific International nak RPE -HKD$428.57 van
- Indosolar nak RPE -₨115.24 van
- Bluejay Mining Plc nak RPE -£95.27 van
- Small Pharma Inc nak RPE -CAD$89.38 van
- Treasury Metals nak RPE -$82.14 van
- Treasury Metals nak RPE -CAD$4.56 van
- Edesa Biotech nak RPE $0.00 van
- medical columbus AG nak RPE €0.45 van
- Nyrstar NV nak RPE €2.96 van
- Talon Metals nak RPE CAD$10.55 van
- Highfield Resources nak RPE AUD$12.94 van
- Venus Metals nak RPE AUD$15.15 van
- Buderim nak RPE AUD$54.64 van